Allelica is an innovative brand that is dedicated to empowering the next generation of clinical genomics. They are at the forefront of reducing the burden of common diseases and increasing equity in genomic medicine across ancestries. Their mission is to advance common disease risk prediction and improve health systems in the US and worldwide.

Allelica offers a range of products and services aimed at achieving this goal. Their flagship product is the Polygenic Risk Score (PRS) test, which utilizes cutting-edge technology to provide accurate and comprehensive risk assessments for various common diseases. The PRS test enables health systems and clinical laboratories to predict, discover, and validate disease risks, particularly in the field of cardiology.

Allelica's team of international scientists is committed to ongoing research and development, ensuring that their products are based on the latest scientific advancements. Their expert advisory board consists of renowned professionals in the field of genomics and medicine, including Robert Green, Aleksandar Rajkovic, Gordon Huggins, Noura Abul-Husn, Bjarni Jóhann Vilhjálmsson, and Alessandro Boccanelli. With their expertise and state-of-the-art products, Allelica is revolutionizing the field of clinical genomics, leading the way in personalized medicine, and improving the lives of people around the world